RT Journal Article
SR Electronic
T1 Mixed ancestry analysis of whole-genome sequencing reveals common, rare, and structural variants associated with posterior urethral valves
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.09.21261801
DO 10.1101/2021.08.09.21261801
A1 Chan, Melanie MY
A1 Sadeghi-Alavijeh, Omid
A1 Stanescu, Horia C
A1 Voinescu, Catalin D
A1 Beaman, Glenda M
A1 Zaniew, Marcin
A1 Weber, Stefanie
A1 Hilger, Alina C
A1 Newman, William G
A1 Woolf, Adrian S
A1 Connolly, John O
A1 Wood, Dan
A1 Stuckey, Alexander
A1 Kousathanas, Athanasios
A1 ,
A1 Kleta, Robert
A1 Bockenhauer, Detlef
A1 Levine, Adam P
A1 Gale, Daniel P
YR 2021
UL http://medrxiv.org/content/early/2021/08/10/2021.08.09.21261801.abstract
AB Posterior urethral valves (PUV) are the commonest cause of end-stage renal disease in children, but the genetic architecture of this disorder remains largely unknown. To address this, we analyzed whole-genome sequencing (WGS) data from 132 unrelated PUV cases and 23,727 controls of mixed ancestry. We observed enrichment of rare structural variation intersecting with candidate cis-regulatory elements, particularly inversions predicted to affect chromatin looping (P=3.1×10-5). We also identified statistically significant associations with common variants at 12q24.21 (P=7.8×10-12; OR 0.4) and uncommon variants at 6p21.1 (P=2×10-8; OR 7.2), that were replicated in an independent European cohort. Bayesian fine mapping and functional annotation mapped these loci to the transcription factor TBX5 and planar cell polarity gene PTK7, respectively, providing insights into the biological pathways underlying PUV. These findings demonstrate that a well-controlled diverse ancestry WGS approach can reveal the genetic architecture of a complex disorder by increasing power for disease locus discovery and facilitating fine-mapping of causal variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. The authors gratefully acknowledge the participation of the patients and their families recruited to the 100,000 Genomes Project. The authors also gratefully acknowledge the participation of the patients and their families in the replication study, the majority of whom were recruited via the CaRE for LUTO Study. MMYC is funded by a Kidney Research UK Clinical Research Training Fellowship (TF_004_20161125). OSA is funded by an MRC Clinical Research Training Fellowship. ACH is supported by a BONFOR-Gerok Grant. WGN, ASW, and GMB are supported by Kidney Research UK (Paed_RP_002_20190925). ASW receives funding from the Medical Research Council (MR/T016809/1). APL is supported by an NIHR Academic Clinical Lectureship. DPG is supported by the St Peters Trust for Kidney, Bladder and Prostate Research. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for The 100,000 Genomes Project was granted by the Research Ethics Committee for East of England Cambridge South (REC Ref 14/EE/1112).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenomic and phenotype data from participants recruited to the 100,000 Genomes Project can be accessed by application to Genomics England Ltd (https://www.genomicsengland.co.uk/about-gecip/joining-research-community/).